Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
H.Res. 1331 is a nonbinding House resolution expressing support for designating June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week." The resolution describes hidradenitis suppurativa (HS) as a chronic inflammatory skin disease that affects millions of Americans and can cause painful nodules, abscesses, scarring, drainage, odor, itching, and significant psychological distress. It emphasizes that HS is frequently misdiagnosed or diagnosed late, which can worsen outcomes and increase healthcare costs.
The resolution also highlights the limited number of FDA-approved biologic therapies for HS and calls attention to the need for more biomedical research, better biomarkers, improved treatment options, and broader access to comprehensive care. It frames public awareness, education, timely diagnosis, and culturally competent care as important goals, and it encourages policies that improve quality of life for patients and caregivers.
Because this is a House resolution, it does not change state law or create enforceable federal requirements. Its practical effect is symbolic: it recognizes an awareness week and signals congressional support for education, research, and improved access to care for people living with hidradenitis suppurativa. The resolution may help elevate attention among health professionals, patient advocates, and policymakers, but it does not directly amend statutes or regulate insurers, providers, or state health systems.
The overall sentiment reflected in the bill text is strongly supportive and advocacy-oriented. The resolution presents HS as a serious, underrecognized disease and argues that greater awareness and research are urgently needed. No votes or committee debate are provided, and the bill was simply referred to the House Committee on Energy and Commerce, so there is no recorded opposition in the supplied materials.
No specific points of contention appear in the provided text or legislative history. The resolution is framed around awareness, diagnosis, research, and access to treatment, which are generally noncontroversial themes. If any disagreement were to arise, it would likely concern the broader policy implications of expanding access to therapies or prioritizing federal attention and research funding, but no such objections are documented here.